[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-462174-105":59,"doc-detail-462174-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","special-issue-special-issue-advances-in-biomedical-and-tissue-engineering-strategies-to-cross-the-blood-brain-barrier-for-next-generation-treatments-against-neurodegenerative-diseases","Special Issue - Special Issue Advances in Biomedical and Tissue Engineering Strategies to Cross the Blood-Brain Barrier for Next-Generation Treatments Against Neurodegenerative Diseases","","Special Issue Editorial introducing advances that cross the blood–brain barrier (BBB) to enable next-generation treatments for neurodegenerative diseases. It frames BBB as a selective obstacle to drug and molecule delivery, where BBB damage promotes neurological disorders through neuroinflammation and harmful infiltration. The collection surveys five research articles and two reviews, emphasizing tissue-engineering solutions from micro- and nanoparticles to advanced in vitro BBB models such as microfluidic platforms and microphysiological systems, alongside in vivo delivery and biomarker strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/special-issue-special-issue-advances-in-biomedical-and-tissue-engineering-strategies-to-cross-the-blood-brain-barrier-for-next-generation-treatments-against-neurodegenerative-diseases/462174/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/special-issue-special-issue-advances-in-biomedical-and-tissue-engineering-strategies-to-cross-the-blood-brain-barrier-for-next-generation-treatments-against-neurodegenerative-diseases/462174.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this Special Issue focus on regarding neurodegenerative diseases?","Question",{"text":112,"@type":113},"It focuses on how the blood–brain barrier limits effective delivery of therapeutic drugs and molecules to the central nervous system, and how BBB disruption can drive disease progression through neuroinflammation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What kinds of strategies are covered in this collection?",{"text":117,"@type":113},"The editorial highlights tissue-engineering and biomedical approaches spanning micro- and nanoparticles, advanced in vitro BBB models (including microfluidic platforms and microphysiological systems), and delivery methods designed to bypass the BBB.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the included studies aim to bypass or model BBB function?",{"text":121,"@type":113},"The research articles describe approaches such as in vivo BBB modulation with imaging readouts, nose-to-brain liposomal delivery in disease models, BBB-on-a-chip microvascular network platforms for targeted transport, and in vitro BBB models for evaluating biomarkers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},462174,1790763493,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":129,"read_time":52,"preview_page_count":19,"preview_urls":143},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Editorial  \nSpecial Issue “Advances in Biomedical and Tissue Engineering Strategies to Cross the Blood–Brain Barrier for Next-Generation Treatments Against Neurodegenerative Diseases”  \nManuele Gori 1, * and Livia La Barbera 2, *  \nReceived: 15 December 2025  \nRevised: 19 December 2025  \nAccepted: 19 December 2025  \nPublished: 20 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Institute of Biochemistry and Cell Biology (IBBC)—National Research Council (CNR), International Campus“A. Buzzati-Traverso”, Monterotondo, 00015 Rome, Italy  \n2 Molecular Neuroscience Unit, Università Campus Bio-Medico di Roma, 00128 Rome, Italy  \n* [Correspondence: manuele.gori@cnr.it](Correspondence: manuele.gori@cnr.it) (M.G.); [l.labarbera@unicampus.it](l.labarbera@unicampus.it) (L.L.B.)  \n1. Introduction  \nThe blood–brain barrier (BBB) is a complex and semipermeable interface between the brain and systemic circulation, which is highly selective to the passage of blood cells, toxic components, nutrients, and metabolites into the central nervous system (CNS) [1] . As such, the BBB represents a major biological obstacle for delivering to the brain therapeutic amounts of drugs and molecules developed to treat neurodegenerative diseases and associated conditions [2,3] . Furthermore, being involved in preserving brain health and CNS homeostasis, BBB damage and disruption contribute to the onset and progression of neurological disorders by enabling the infiltration of harmful molecules and neurotoxic pathogens that trigger neuroinflammation [4–6] . Innovative strategies and improved drug delivery systems are therefore essential to bypass this natural shield and provide the CNS with targeted treatments and reliable diagnostics. Parallel efforts in bioengineering are equally crucial for developing advanced in vitro BBB models that more faithfully recapitulate the structure and function of this physiological barrier.  \nThis Special Issue covers a set of 5 research articles and 2 reviews that explore the role played by the BBB in the context of neurological disorders. The present article collection provides an in-depth overview of the most recent tissue-engineering strategies to tackle neurodegenerative diseases, using groundbreaking solutions and pioneering biomedical approaches, ranging from micro-and nanoparticles to advanced in vitro models of the BBB, including microfluidic platforms and microphysiological systems.  \nIn the first research article, Sampedro-Viana and coworkers highlight the importance of reliable in vivo models of chronic BBB dysfunction for dissecting the role of the BBBin neurological disorders in order to facilitate the effective delivery of drugs into the brain. The Authors developed an in vivo model of transient BBB opening, through an osmotic disruption mechanism, via periodic intravenous administration of mannitol over 12 weeks in healthy adult rats. This method, due to the induction of osmotic stress, caused a transient BBB opening and dysfunction (BBB leakage patterns) . These phenomena were detected in a non-invasive manner using a sensitive contrast-enhanced magnetic resonance imaging (MRI)-based method. Furthermore, the Authors identified an association between osmotic BBB disruption and region-specific alterations in brain metabolism (i.e., specific metabolite signature) via real-time MR spectroscopy, as well as a link between chronic BBB dysfunction and neuroinflammation, by analyzing serum levels of pro-inflammatory cytokines (Contribution 1) .  \nIn the second research article, Lee and colleagues leveraged the potential of liposomes for the treatment of Alzheimer’s disease (AD) through the nose-to-brain delivery of three drugs (i.e., donezepil, memantine and BACE-1 siRNA) in a transgenic mouse model of AD. The intranasal administration of liposomes re","cbCaimTBXDgEsd55","https://ap.wps.com/l/cbCaimTBXDgEsd55","pdf",175389,"English","# Introduction\n## Scope of the Special Issue\n## Highlights of Included Research Articles","[{\"question\":\"What problem does this Special Issue focus on regarding neurodegenerative diseases?\",\"answer\":\"It focuses on how the blood–brain barrier limits effective delivery of therapeutic drugs and molecules to the central nervous system, and how BBB disruption can drive disease progression through neuroinflammation.\"},{\"question\":\"What kinds of strategies are covered in this collection?\",\"answer\":\"The editorial highlights tissue-engineering and biomedical approaches spanning micro- and nanoparticles, advanced in vitro BBB models (including microfluidic platforms and microphysiological systems), and delivery methods designed to bypass the BBB.\"},{\"question\":\"How do the included studies aim to bypass or model BBB function?\",\"answer\":\"The research articles describe approaches such as in vivo BBB modulation with imaging readouts, nose-to-brain liposomal delivery in disease models, BBB-on-a-chip microvascular network platforms for targeted transport, and in vitro BBB models for evaluating biomarkers.\"}]","Special Issue - Special Issue Advances in Biomedical and Tissue Engineering Strategies to Cross the Blood-Brain Barrier for Next-Generation Treatments Against Neurodegenerative Diseases | PDF",[144,148,152,156],{"page_no":8,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/1f48c73e3b14012c71ff7627ce980096.webp",983,1390,{"page_no":14,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/bf9668cd29f906098d6137d0480e60f2.webp",982,1388,{"page_no":81,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/3176e65bb37da917d721aada1e5e63cf.webp",981,1387,{"page_no":19,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/ca922c7c37ec72d96e1b0a603a8b8368.webp",980,1385]